Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Depression strongly predicts absenteeism among patients with chronic constipation

17 Jan 2017

Absenteeism among patients with chronic constipation appear to have a stronger association with depression than symptom severity, according to a recent study, suggesting that a portion of the indirect costs of chronic constipation is attributable to depression.

Researchers examined 148 consecutive patients with chronic constipation (mean age 43 years; 87 percent female) to determine the patient characteristics associated with increased absenteeism and Emergency Department (ED) utilization.

Disease severity, quality of life, somatization and psychiatric comorbidities were assessed using standardized instruments. Multivariable logistic regression facilitated identification of the predictors of work and school absenteeism, as well as ED visits for constipation.

Of the patients, 21.6 percent had high absenteeism, and 24.3 percent visited the ED for constipation in the past year. Chronically constipated patients with high absenteeism and ED visits were more likely to be depressed (56.3 vs 18.5 percent for high absenteeism; p<0.0001; 47.2 vs 19.6 for ED visits; p<0.01).

On analyses, depression was associated with a 4.41-fold increase in the risk of absenteeism (p<0.01). Additionally, a trend toward an association between depression and ED visits (OR, 2.57; p=0.067) was observed.

There was no association between symptom severity and high absenteeism or ED utilization.

The present data suggest that depression, but not symptom severity, strongly predicts absenteeism among patients with chronic constipation.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.